The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring
Open accessAbstract
enzyme CYP2C19 is one of the major determinants of the VRCZ blood level.The frequency of poor metabolizers (PM), with defective or diminished metabolic capacity, is higher among Japanese patients.Variability in the plasma concentrations, arising from these previously mentioned aspects, may lead to variability in efficacy or toxicity.Determining the plasma concentration is indicated in some situations to guide dosing and to individualize and improve the treatment options, resulting in a better therapeutic outcome or fewer side effects.In this guideline, we review the factors that influence the VRCZ pharmacokinetic profile, the data supporting exposure-effect and exposure-toxicity relationships that make broad recommendations for therapeutic drug monitoring difficult for VRCZ, and provide indications for which therapeutic drug monitoring is reasonable based on currently available data (for example, in children).We also outline ways in which the existing problems can be solved. MethodsThe practice guidelines for therapeutic drug monitoring (TDM) of VRCZ were reviewed by a practice guideline committee, consisting of 18 experts in the field of TDM (Expert Panel) convened from the Japanese Society of Chemotherapy (JSC) and the Japanese Society of Therapeutic Drug Monitoring (JSTDM).The Expert Panel reviewed papers published since 2000 and additionally analyzed data before 1999, if necessary.Computerized PUBMED searches of the English-language literature and Igaku-Chuo-Zasshi searches of the Japanese-language literature were performed using the terms ''voriconazole'' and ''therapeutic drug monitoring'' and focused mainly on human studies; however, animal studies and in vitro data were included if necessary.The committee specifically looked for existing randomized clinical trials and existing meta-analysis using a general database (i.e., MEDLINE, EMBASE), and the Cochrane Library (both The Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effectiveness); however, few randomized clinical trials and meta-analyses were available and many recommendations were developed from observational studies or small case studies.To evaluate evidence regarding TDM, the Expert Panel followed the Canadian Task Force recommendations [3], which included a systematic weighting of the quality of the evidence and a graded recommendation according to the Minds classification (Table 1).The Expert Panel met in person on 7 occasions and by E-mail via mailing lists on 533 occasions.The draft guidelines for the executive summary were placed on the homepage of the JSC and JSTDM.Feedback from external public comments was obtained between April 9, 2012, and May 8, 2012.The guidelines for the Japanese version were approved by the JSC and JSTDM Board of Directors and were published in the Japanese Journal of Chemotherapy in June 2012.All the members of the practice guideline committee complied with the JSC policy on conflicts of interest, which requires the disclosure of any financial or other interest that Table 1 Grading system for ranking recommendations and evidence level adopted in the guideline Category, grade Definition Strength of recommendation A Good evidence to support a recommendation for use B Moderate evidence to support a recommendation for use C1 Recommendation for use regardless of poor evidence C2 Poor evidence to support a recommendation for use D Good-to-moderate evidence to support a recommendation against use Quality of evidence I Evidence from C1 properly randomized, controlled trial II Evidence from C1 well-designed clinical trial, without randomization from cohort or case-controlled analytical studies, multiple time-series, or dramatic results from uncontrolled experiments.III Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941 · cited 1×
“(c) Patients with hepatic dysfunction: In a multiple-dose study, patients with Child–Pugh class [50] A and B liver dysfunction who received a 50 % reduced VRCZ maintenance dose achieved a mean AUC24 of 56.”
BackgroundRybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 2×
“Steady-state concentrations are achieved only after 5–6 days but, if a loading dose is given, earlier steady-state concentrations are obtained [39]; therefore, a loading dose of 6 mg/kg every 12 h for 2 doses in patients with intravenous administration and 300 mg every 12 h for 2 doses in oral administration is requir…”
BackgroundKullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463 · cited 4×
“[25] reported that initial VCM trough \15 lg/ml was an independent predictor of VCM failure in patients with MRSA bacteremia.”
BackgroundInfluentialFridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231 · cited 1×
“was strongly predictive of the treatment outcomes [25].”
Background
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
He, N., Su, S., Ye, Z., Du, G., He, B., Li, D., Liu, Y., Yang, K., Zhang, X., Zhang, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1536 · Cited by 155
Metadata
- Authors
- Hamada, Y., Tokimatsu, I., Mikamo, H., Kimura, M., Seki, M., Takakura, S., Ohmagari, N., Takahashi, Y., Kasahara, K., Matsumoto, K., Okada, K., Igarashi, M., Kobayashi, M., Mochizuki, T., Nishi, Y., Tanigawara, Y., Kimura, T., & Takesue, Y.
- Venue
- Journal of Infection and Chemotherapy
- Publisher
- Elsevier BV
- Published
- 2013
- Volume
- 19
- Issue
- 3
- Pages
- 381-392
- ISSN
- 1341-321X (ISSN-L)
- OpenAlex
- W2106444474
- Cited by
- 248
- References
- 6
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. https://app.cochat.ai/papers/10.1007/s10156-013-0607-8
- The paper
- Hamada, Y., Tokimatsu, I., Mikamo, H., Kimura, M., Seki, M., Takakura, S., Ohmagari, N., Takahashi, Y., Kasahara, K., Matsumoto, K., Okada, K., Igarashi, M., Kobayashi, M., Mochizuki, T., Nishi, Y., Tanigawara, Y., Kimura, T., & Takesue, Y. (2013). Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Journal of Infection and Chemotherapy. https://doi.org/10.1007/s10156-013-0607-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.